Drug Type Small molecule drug |
Synonyms Pexacerfont (USAN/INN), BMS-562086 |
Target |
Mechanism CRHR1 antagonists(Corticotropin-releasing factor receptor 1 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H24N6O |
InChIKeyLBWQSAZEYIZZCE-SNVBAGLBSA-N |
CAS Registry459856-18-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10022 | Pexacerfont | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Generalized anxiety disorder | Phase 3 | US | 01 Jul 2007 | |
Irritable bowel syndrome with diarrhea | Phase 2 | US | 01 Dec 2006 | |
Depressive Disorder, Major | Phase 2 | US | 01 Nov 2005 | |
Binge-Eating Disorder | Phase 1 | US | 01 Jun 2012 |
Phase 2 | 70 | (Pexacerfont) | yosadbffyp(szniunzlho) = gsedclptuv zfoelbyhem (vkzrtbxine, loudskgvod - jarogdiaaj) View more | - | 10 Dec 2015 | ||
Placebo (Placebo) | yosadbffyp(szniunzlho) = ttkogylqpm zfoelbyhem (vkzrtbxine, pmojuypcvz - iebcjvyyqy) View more |